Scharnagl H - Search Results

1

Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate.

Spaniol M, Kaufmann P, Beier K, Wüthrich J, Török M, Scharnagl H, März W, Krähenbühl S. Spaniol M, et al. Among authors: scharnagl h. J Lipid Res. 2003 Jan;44(1):144-53. doi: 10.1194/jlr.m200200-jlr200. J Lipid Res. 2003. PMID: 12518033 Free article.

2

A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity.

Scharnagl H, März W, Schliack M, Löser R, Gross W. Scharnagl H, et al. J Lipid Res. 1995 Mar;36(3):622-7. J Lipid Res. 1995. PMID: 7775873 Free article.

3

Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts.

Feussner G, Scharnagl H, Scherbaum C, Acar J, Dobmeyer J, Lohrmann J, Wieland H, März W. Feussner G, et al. Among authors: scharnagl h. J Lipid Res. 1996 Aug;37(8):1632-45. J Lipid Res. 1996. PMID: 8864947 Free article.

4

Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.

März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H. März W, et al. Among authors: scharnagl h. J Lipid Res. 1998 Mar;39(3):658-69. J Lipid Res. 1998. PMID: 9548597 Free article.

5

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.

Winkler K, Scharnagl H, Tisljar U, Hoschützky H, Friedrich I, Hoffmann MM, Hüttinger M, Wieland H, März W. Winkler K, et al. Among authors: scharnagl h. J Lipid Res. 1999 Mar;40(3):447-55. J Lipid Res. 1999. PMID: 10064733 Free article.

6

Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

Gierens H, Nauck M, Roth M, Schinker R, Schürmann C, Scharnagl H, Neuhaus G, Wieland H, März W. Gierens H, et al. Among authors: scharnagl h. Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1777-83. doi: 10.1161/01.atv.20.7.1777. Arterioscler Thromb Vasc Biol. 2000. PMID: 10894816

7

Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.

Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W. Hoffmann MM, et al. Among authors: scharnagl h. J Am Soc Nephrol. 2001 Mar;12(3):524-530. doi: 10.1681/ASN.V123524. J Am Soc Nephrol. 2001. PMID: 11181800

8

Apolipoprotein E3Basel: new insights into a highly conserved protein region.

Miserez AR, Scharnagl H, Muller PY, Mirsaidi R, Stähelin HB, Monsch A, März W, Hoffmann MM. Miserez AR, et al. Among authors: scharnagl h. Eur J Clin Invest. 2003 Aug;33(8):677-85. doi: 10.1046/j.1365-2362.2003.01180.x. Eur J Clin Invest. 2003. PMID: 12864777

9

Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol.

Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Scharnagl H, et al. Am J Cardiol. 2004 Jan 15;93(2):219-20. doi: 10.1016/j.amjcard.2003.09.045. Am J Cardiol. 2004. PMID: 14715353 Clinical Trial.

10

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism.

Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, März W. Scharnagl H, et al. Contraception. 2004 Feb;69(2):105-13. doi: 10.1016/j.contraception.2003.10.004. Contraception. 2004. PMID: 14759614 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

296 results

Search Page

Filters